// App-Quantinova.ai

: Safety of BXCL701, a small molecule inhibitor of dipeptidyl peptidases (DPP), with pembrolizumab, (pembro, anti-PD-1) monoclonal antibody, in men with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Rahul Raj Aggarwal

Principal Investigators

  • Dan Costin

  • Vincent J. O'Neill

  • Cedric R Burg

  • Diane I. Healey

  • Johann S. De Bono

  • Jingsong Zhang

  • Eric Jay Small

Medical Centers

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Center for Cancer Care at White Plains Hospital, White Plains, NY

  • Bioxcel Therapeutics, New Haven, CT

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Programmed death-ligand 1

  • Prostate specific antigen

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Fixed Dose

  • Multicenteric

Phase

  • NA

Study Id's

  • NCT03910660

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved